Browse drugs

…ever, these studies did not employ suitable active comparators. Metformin is often prescribed as first-line therapy in T2DM management, w…

…ilar course in their T2DM trajectory compared with those not on metformin). For individuals with multiple COVID-19 tests, we excluded all…

… The proportion of guideline-directed treatment was suboptimal: sodium-glucose cotransporter-2 inhibitors (36.5%), renin-angiotensin system inhibitors (56.5%) and only 3…

…the consolidation of four foundational pharmacological pillars: beta-blockers, renin-angiotensin system inhibitors or angiotensin receptor-ne…

…tients to receive new SGLT2i (RR 0.59, 95% CI 0.42 to 0.82) and GLP-1RA (RR 0.62, 95% CI 0.49 to 0.79) prescriptions; Hispanic patients…

…cial in these patients. Remarkably, the benefits of GLP-1RA and SGLT2i are independent of type 2 diabetes status or baseline renal fun…

…g reports of suicidal ideation and behaviors in patients taking GLP-1 RAs. This study assessed a potential association with intentional s…

…CI −0.53 to 0.86 events per 1000 person-years) or compared with DPP-4is (HR 0.94; 95% CI 0.71 to 1.24, rate difference −0.18; 95% CI −0…

…ng renin-angiotensin-aldosterone system inhibitors (RAASi) with dapagliflozin compare to RAASi alone in children with hereditary kidney disea…

…stic accuracy of HFpEF Scores versus inclusion criteria used in sodium-glucose cotransporter-2 inhibitors (SGLT2i) trials, age-adjusted N-terminal pro B-type natriuretic…

…e estimated the comparative effect of incretin-based therapies (GLP-1RA and dipeptidyl-peptidase-4 inhibitors (DPP-4i)) versus sodium-g…

…odium-glucose cotransporter-2 inhibitors, and 3% were receiving glucagon-like peptide-1 analogues.Conclusions The prevalence of eASCVD and high risk for ASCVD in…